Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MBX

+ Watchlist+ Portfolio

MBX Biosciences, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$53.42
52-Week Range
$26.00 – $72.64
Market Cap
$2.65B
P/E (TTM)
—
EPS (TTM)
-3.03
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.61
PEG Ratio
—
Return on Equity
-33.72%
Return on Assets
-22.25%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
19.58
Debt/Equity
0.01
Total Debt
$3.29M
Free Cash Flow
$-54.00M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$2.17B

Market Snapshot

About

MBX Biosciences, Inc. is a clinical-stage precision endocrinology company developing peptide-based therapeutics for endocrine and metabolic disorders. The company focuses on diseases caused by hormonal imbalances, including hypoparathyroidism, post-bariatric hypoglycemia, and growth hormone deficiency. Their approach targets specific receptors to restore normal physiological function.